Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Inclusion Criteria:

- Age 18 to 55 years (inclusive)

- Diagnosis of PPMS in accordance with the revised 2010 McDonald criteria and the
presence or documented history of cerebrospinal fluid oligoclonal bands by
isoelectric focusing or elevated immunoglobulin G (IgG) index

- Expanded Disability Status Score (EDSS) of 2.0 to 6.5 points at screening

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods that result in a failure rate
of less than (<)1 percent (%) per year during the treatment period and for at least
24 weeks after the last dose of study treatment or until their B-cells have repleted,
whichever is longer

Exclusion Criteria:

- History of relapsing-remitting multiple sclerosis (RRMS), progressive relapsing
multiple sclerosis (PRMS) or secondary progressive multiple sclerosis (SPMS) at
screening

- History of severe allergic or anaphylactic reactions to humanized or murine
monoclonal antibodies

- History or known presence of recurrent or chronic infection

- History of recurrent aspiration pneumonia requiring antibiotic therapy

- History of cancer, including solid tumors and hematological malignancies (except
basal cell, in situ squamous cell carcinomas of the skin, and in situ carcinoma of
the cervix of the uterus that have been excised and resolved with documented clean
margins on pathology)

- History of or currently active primary or secondary immunodeficiency

- History of coagulation disorders because ocrelizumab is administered via infusion

- Known presence or history of other neurologic disorders

- Significant, uncontrolled disease, such as cardiovascular (including cardiac
arrhythmia), pulmonary (including chronic obstructive pulmonary disease), renal,
hepatic, endocrine, gastrointestinal, or any other significant disease

- Congestive heart failure

- Known active bacterial, viral, fungal, mycobacterial infection, or other infection

- Any concomitant disease that may require chronic treatment with systemic
corticosteroids or immunosuppressants during the course of the expanded access
program (EAP)

- Contraindications for or intolerance to oral or IV corticosteroids, including IV
methylprednisolone

- Treatment with therapies approved for relapsing forms of Multiple Sclerosis (MS),
including: Beta interferons, glatiramer acetate, fingolimod (Gilenya®), teriflunomide
(Aubagio®), dimethyl fumarate (Tecfidera®), IV immunoglobulin, plasmapheresis, or
other immunomodulatory therapies within 12 weeks prior to enrollment (Participants
should not be excluded from the EAP due to previous treatment with rituximab)

- Participants who have received fingolimod (Gilenya®) or dimethyl fumarate
(Tecfidera®) if their lymphocyte count is not within normal values

- Previous treatment with natalizumab (Tysabri®) within 6 months of screening
(Participants are not eligible for the EAP if they have been treated with natalizumab
(Tysabri) for more than 1 year)

- Any previous treatment with alemtuzumab (Lemtrada®)

- Any previous or current treatment with any experimental procedure for MS